News

3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.

At the closing of the fifth edition of the Master in Galenic Design and Manufacturing in the Pharmaceutical Industry of the University of Navarra.

The prestigious ranking is based on an exhaustive questionnaire that Actualidad Económica prepares and publishes every year, and which seeks to evaluate and reward those companies whose human resources management makes them benchmarks.

Kenneth McMahon has a PhD in molecular microbiology and a solid experience of over 10 years in both Quality Assurance (QA) and Quality Control (QC) departments.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.

The award forms part of an agreement between 3P and the Faculty of Pharmacy at the University of Navarra promoting digital transformation and professional training within the pharmaceutical industry.

3P Biopharmaceuticals, a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO) makes financial and material donations to help Ukraine.